Ardelyx | ARDX - Selling And Administration Expenses

Stock Price
6.59
Daily Change
0.07 1.07%
Monthly
22.04%
Yearly
15.82%
Q3 Forecast
6.47

Ardelyx reported $83.99M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 466.77M
Cash and Equivalent USD 90.04M
Cost of Sales USD 14.82M
Current Assets USD 351.57M
Current Liabilities USD 81.72M
Debt USD 206.64M
Dividend Yield -6.39
EBIT USD -12.5M
EBITDA USD -11.87M
Employees 395
EPS Earnings Per Share USD -0.08
Equity Capital and Reserves USD 139.53M
Gross Profit on Sales USD 82.84M
Interest Expense on Debt USD 6.58M
Loan Capital USD 229.21M
Market Capitalization USD 1.52B
Net Income USD -19.08M
Operating Expenses USD 112.06M
Operating Profit USD -14.4M
Ordinary Share Capital USD 240.77M
Pre-Tax Profit USD -19.08M
Sales Revenues USD 97.66M
Selling and Administration Expenses USD 83.99M
Stock USD 22.28M
Trade Creditors USD 21.68M
Trade Debtors USD 62.55M

Selling And Administration Expenses Change Date
Abbott USD 3.09B 39M Jun/2025
Amgen USD 1.69B 4M Jun/2025
Ardelyx USD 83.99M 7.92M Jun/2025
Corcept Therapeutics USD 103.85M 13.19M Jun/2025
Life Technologies USD 4.93M 1.34M Jun/2025
Sanofi EUR 2.32B 1.08B Jun/2025
TG Therapeutics USD 12.04M 38.29M Jun/2025
United Therapeutics USD 212.5M 42.4M Jun/2025